Disease Mongering of Age‐Associated Declines in Testosterone and Growth Hormone Levels
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
A combination of direct-to-consumer product advertising (DTCPA) and lax consensus guidelines for testosterone prescribing have, over the past decade, led to 10- and 40-fold increases in testosterone prescriptions in the United States and Canada, respectively, with Internet pharmacies playing a major role in the latter's increase.1 U.S. pharmaceutical sales of testosterone increased from $324 million in 2002 to $2 billion in 2012, and the number of testosterone doses prescribed climbed from 100 million in 2007 to half a billion in 2012, not including the additional contributions from compounding pharmacies, Internet, and direct-to-patient clinic sales.1, 2 On September 17, 2014, the U.S. Food and Drug Administration (FDA) convened a meeting to address concerns that many men are receiving testosterone who should not and because of reports of adverse cardiovascular events in men using testosterone.3 We join others who characterize the mass marketing of testosterone coupled with the permissive prescribing of testosterone for common, nonspecific, aging-related symptoms as disease mongering of declines in testosterone with advancing age.4, 5 Disease mongering is defined as "the selling of sickness that widens the boundaries of illness and grows the markets for those who sell and deliver treatments."6 The prescribing of growth hormone for "antiaging" or "age management" is another example of disease mongering. DTCPA is the mass marketing component of disease mongering of age-related declines in testosterone. With advertising directed primarily at baby boomers, age-related complaints such as "slowing down" and low libido are attributed to catchy medicalized sounding syndromes like "low T" and "andropause."7, 8 These syndromes are likened to menopause, which is a false and misleading analogy because middle-aged men do not experience any universal or sharp decline in serum testosterone.9 The pharmaceutical industry asserts that DTCPA is an important service to the public that helps people and their doctors become aware of treatable medical problems.10 However, when sophisticated mass marketing is directed toward people lacking the technical expertise to critically evaluate the deceptively simplified medical science claims that such advertising makes, there is ample opportunity for disease mongering. Because doctors are the prescription gatekeepers, these advertisements can effectively pit patients against their doctors, pressuring them for compliant prescribing on demand and distorting clinical judgment. As a result, recognizing the dangers, nearly all countries prohibit DTCPA, except Canada, New Zealand, and the United States.10 The other enabler of disease mongering of age-related declines in testosterone is lax professional consensus panel prescribing guidelines. Guidelines created over the last decade, some sponsored by manufacturers of testosterone products,11 have stretched the definition of hypogonadism, a clinical disorder of the hypothalamus–pituitary–testicular axis that has a pathological basis, to include functional disorders so as to include men with an unexplained low serum testosterone level (without any underlying reproductive pathology) accompanied by complaints that are commonly associated with classical hypogonadism but also many age-related comorbidities. Marketers of "low T" have capitalized upon the nonspecificity of these age-related symptoms by encouraging men to take questionnaires of equally low specificity focusing on common complaints such as low energy, feeling sad, sleep problems, decreased physical performance, or increased fat.12 Notably, in middle-aged and older men who report excellent health, aging is not associated with a decrease in serum testosterone,13 highlighting the effect of age-associated comorbidities rather than age itself upon testosterone levels. These nonreproductive disorders, such as obesity,14 may invoke adaptive responses of an intact reproductive system, the net effects of which, a priori, may be beneficial, neutral, or adverse. The appropriate treatment for such functional declines in serum testosterone is not testosterone but reversing the underlying condition. Because unselected aging men with comorbidities will display a gradual decrease in serum testosterone with age, using any fixed serum testosterone threshold, the proportion of men with a "low" serum testosterone will automatically increase with age and be mislabeled as "late-onset hypogonadism." This has led to claimed prevalences of age-related hypogonadism of up to 40%,15 representing an almost 100-times larger market size over the estimated age-invariant prevalence of 0.5% of men who have testosterone deficiency due to a pathological disruption of the hypothalamus–pituitary–testicular axis.16 In an attempt to define a more-specific syndrome of "late-onset hypogonadism," the latest medicalized term for "low T" or "andropause," Wu and colleagues compared men with low serum testosterone with those with no
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of late-onset hypogonadism in middle-aged and elderly men
Wu, F. C. W., Tajar, A., Beynon, J. M., Pye, S. R., Silman, A. J., Finn, J. D., O'Neill, T. W., Bartfai, G., Casanueva, F. F., Forti, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0911101 · Cited by 1,544 · cited 1×
“6% for men aged 50 to 59.(17) Yet in 2013, reflecting the effectiveness of DTCPA’s targeting of baby boomers, insured men aged 40 to 64 comprised 62.”
BackgroundPrevalence of hypogonadism in males aged at least 45 years: the HIM study
MULLIGAN, T., FRICK, M. F., ZURAW, Q. C., STEMHAGEN, A., & MCWHIRTER, C. (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2006.00992.x · Cited by 767
Lowered testosterone in male obesity: Mechanisms, morbidity and management
Grossmann, M., Tang Fui, M., & Dupuis, P. (2014) · Asian Journal of Andrology · doi:10.4103/1008-682x.122365 · Cited by 293
Handelsman, D. J. (2013) · Medical Journal of Australia · doi:10.5694/mja13.10111 · Cited by 253
Self-citationSartorius, G., Spasevska, S., Idan, A., Turner, L., Forbes, E., Zamojska, A., Allan, C. A., Ly, L. P., Conway, A. J., McLachlan, R. I., et al. (2012) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2012.04432.x · Cited by 209
Self-citationComparison of screening questionnaires for the diagnosis of hypogonadism
Morley, J. E., Perry, H. M., Kevorkian, R. T., & Patrick, P. (2006) · Maturitas · doi:10.1016/j.maturitas.2005.07.004 · Cited by 168
Cited by
Testosterone treatment and risk of venous thromboembolism: population based case-control study
Martinez, C., Suissa, S., Rietbrock, S., Katholing, A., Freedman, B., Cohen, A. T., & Handelsman, D. J. (2016) · BMJ · doi:10.1136/bmj.i5968 · Cited by 181
Self-citationYeap, B. B., Grossmann, M., McLachlan, R. I., Handelsman, D. J., Wittert, G. A., Conway, A. J., Stuckey, B. G., Lording, D. W., Allan, C. A., Zajac, J. D., et al. (2016) · Medical Journal of Australia · doi:10.5694/mja16.00393 · Cited by 135
Self-citationGolan, R., Scovell, J. M., & Ramasamy, R. (2015) · The Aging Male · doi:10.3109/13685538.2015.1052392 · Cited by 73
Wentzell, E. (2017) · The Journal of Sex Research · doi:10.1080/00224499.2016.1259386 · Cited by 26
Testosterone treatment in older men
(2016) · New England Journal of Medicine · doi:10.1056/nejmc1603665 · Cited by 25
Irrational Exuberance in Testosterone Prescribing: When Will the Bubble Burst?
Handelsman, D. J. (2015) · Medical Care · doi:10.1097/mlr.0000000000000416 · Cited by 22
“On the basis of pharmaceutical industry sales data per capita, this featured a 10-fold increase in the United States and 40-fold increase in Canada of testosterone use, now revealing a $2 billion per annum market for testosterone reflecting a 100-fold increase over 3 decades ago.(2,3) Such stunning increases (which ex…”
BackgroundSelf-citation
Metadata
- Authors
- Perls, T., & Handelsman, D. J.
- Venue
- Journal of the American Geriatrics Society
- Publisher
- Wiley
- Published
- 2015-03-24
- Volume
- 63
- Issue
- 4
- Pages
- 809-811
- ISSN
- 0002-8614 (ISSN-L)
- 1532-5415
- OpenAlex
- W2075261640
- Cited by
- 47
- References
- 6
- FWCI
- 7.34
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.